Prevalence of Human Immunodeficiency Virus Type 1 Drug Resistance Associated Mutations in Protease Cleavage and Non-Cleavage Sites and PTAP Motif Duplications in Indian HIV-1 Subtype C gag Regions
نویسندگان
چکیده
The HIV-1 protease is responsible for the cleavage of Gag, Gag-Pol and Nef precursor polyproteins. The process, occurring late in viral cycle, is highly specific, temporally regulated and essential for the production of infectious viral particles (Jacks et al., 1988; Krausslich et al., 1989; Swanstrom et al., 1997). For the generation of a mature and viable virion, separate twelve proteolytic reactions are required, with individual reaction occurring at a specific cleavage site with unique amino acid arrangement (Billich International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 5 (2017) pp. 1322-1330 Journal homepage: http://www.ijcmas.com
منابع مشابه
HIV-1 protease-substrate coevolution in nelfinavir resistance.
UNLABELLED Resistance to various human immunodeficiency virus type 1 (HIV-1) protease inhibitors (PIs) challenges the effectiveness of therapies in treating HIV-1-infected individuals and AIDS patients. The virus accumulates mutations within the protease (PR) that render the PIs less potent. Occasionally, Gag sequences also coevolve with mutations at PR cleavage sites contributing to drug resis...
متن کاملResistance mechanism of human immunodeficiency virus type-1 protease to inhibitors: A molecular dynamic approach
Human immunodeficiency virus type 1 (HIV-1) protease inhibitors comprise an important class of drugs used in HIV treatments. However, mutations of protease genes accelerated by low fidelity of reverse transcriptase yield drug resistant mutants of reduced affinities for the inhibitors. This problem is considered to be a serious barrier against HIV treatment for the foreseeable future. In this st...
متن کاملTransient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations.
Cleavage of the group-specific antigen (Gag) polyprotein by HIV-1 protease represents the critical first step in the conversion of immature noninfectious viral particles to mature infectious virions. Selective pressure exerted by HIV-1 protease inhibitors, a mainstay of current anti-HIV-1 therapies, results in the accumulation of drug resistance mutations in both protease and Gag. Surprisingly,...
متن کاملDrug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
Two different responses to the therapy were observed in a group of patients receiving the protease inhibitor indinavir. In one, suppression of virus replication occurred and has persisted for 90 weeks (bDNA, < 500 human immunodeficiency virus type 1 [HIV-1] RNA copies/ml). In the second group, a rebound in virus levels in plasma followed the initial sharp decline observed at the start of therap...
متن کاملVariability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?
Naturally occurring polymorphisms in the protease of human immunodeficiency virus type 1 (HIV-1) subtype C would be expected to lead to adaptive (compensatory) changes in protease cleavage sites. To test this hypothesis, we examined the prevalences and patterns of cleavage site polymorphisms in the Gag, Gag-Pol, and Nef cleavage sites of C compared to those in non-C subtypes. Codon-based maximu...
متن کامل